Try searching for...

      Dr Aflah Roohullah
      /content/dam/genesiscare/headshots/au-doctor-headshots/AU_Oncology_Headshot_GA_Dr_Aflah _Roohullah.jpg
      Medical Oncologist

      Dr Aflah Roohullah

      Dr Aflah Roohullah
      Dr
      Aflah
      Roohullah

      MBChB, FRACP, PhD

      For patients/carers

      For doctors

      MBChB, FRACP, PhD

      Locations

      NSW:Campbelltown
      Campbelltown, NSW
      Campbelltown
      38 Camden Road, Campbelltown, NSW, 2560, Australia
      -34.071101399509224, 150.80602556751086
      /au/our-centres/nsw-campbelltown
      NSW

      Languages

      Fluent

      • English

      Conversational

      • Arabic / العربية
      • Urdu / اردو

      Biography

      Clinical interest in Lower Gastrointestinal (GI), Upper Gastrointestinal (GI), Carcinoma of unknown primary, Gynaecological plus Head and Neck cancers

      Dr Aflah Roohullah graduated from the University of Otago in 2004 and has worked as staff specialist in the South West Sydney region for the last 10 years serving the Campbelltown and Liverpool community, covering multiple cancer types, however primarily focusing on lower and upper gastrointestinal (GI) cancers.

      Dr Roohullah is an active member of multiple multidisciplinary team meetings (MDTs) including the upper GI, colorectal MDT, and gynaecological MDT. Dr Roohullah is active and has experience in phase 1 clinical trials, and additionally has been a principal investigator for multiple clinical trials.

      Dr Roohullah has previously served as the head of department for medical oncology at Liverpool and is currently a senior lecturer at Western Sydney University. He is also the current chair of the medical oncology advanced training committee for the RACP.

      More information

      Research interests
      • Long-standing experience in phase 1 clinical trials including first in human studies
      • Principal Investigator (PI) for multiple trials and recruited to over 30 studies
      • Awarded PhD on translational studies in phase 1 trials in 2024
      Professional memberships
      • AACR
      • MOGA
      • RACP